Covid19 Primer

Title	Date	Topic	Relevance
1958. Longitudinal SARS-COV-2 anti-spike antibody response in pregnant people with natural infection and variable vaccine uptake Sylvia M LaCourse et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	1.0
1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination Magdalena E Sobieszczyk et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.9
1140. Outcomes and Complications of Tocilizumab and Baricitinib use in Transplant Patients with COVID-19 Maria A Mendoza et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
1396. COVID-19 Hospitalization Impact of Age, Race and Ethnicity Among Medicaid and Uninsured Mamta K Jain et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
1065. Patient-Reported Reasons for Non-Participation in Inpatient COVID-19 Clinical Research: Results from a Multi-Center VA Embedded Randomized Trial Samira Reyes Dassum et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro Julie Strizki et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
1132. Integrated Quantitative Systems Pharmacology (QSP) Characterizing Viral Dynamics After Intramuscular (IM) Adintrevimab (ADI) Administration in Participants with Mild to Moderate Coronavirus Disease (COVID-19) Evan Tarbell et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
282. Occurrence of adverse events and factors related to prognosis in a cohort of patients hospitalized with COVID-19 at University hospital - UNICAMP, Brazil. Maitê V Luz et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
1331. Pneumococcal Colonization Among Children 5 years of Age and Younger During SARS-CoV-2 Pandemic Liset Olarte et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.2
1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults Gustavo H Kijak et al in open forum infectious diseases (3.835) Source crossref_works_2020_03_25	Dec 15, 2022	Grant/Research Support & Advisor/Consultant	0.3